TCS/PR/SE-124/2019-20

December 6, 2019

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Mumbai - 400051
Symbol - TCS

BSE Limited
P. J. Towers, Dalal Street,
Mumbai -400001
Scrip Code No. 532540 (BSE)

Dear Sirs,

We are sending herewith copy of the Press Release titled **"TCS' Advanced Drug Development Suite Wins the India Pharma Award 2019"** which will be disseminated shortly.

The Press release is self-explanatory.

Thanking you,

Yours faithfully,
For **Tata Consultancy Services Limited**

Rajendra Moholkar
Company Secretary

TATA CONSULTANCY SERVICES
Tata Consultancy Services Limited
9th Floor Nirmal Building Nariman Point Mumbai 400 021
Tel 91 22 6778 9595 Fax 91 22 6778 9660 e-mail corporate.office@tcs.com website www.tcs.com
Corporate Identification No. (CIN): L22210MH1995PLC084781

For immediate use **PRESS RELEASE**

TCS' Advanced Drug Development Suite Wins the India Pharma Award 2019

Tata Consultancy Services' Cloud-based ADD Suite Received the Recognition for Leveraging Automation, AI and IoT to Digitally Transform Clinical Trials

NEW DELHI | MUMBAI, December 6, 2019: Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting, and business solutions organization, announced that its cloud-based clinical solutions and services suite, TCS Advanced Drug Development (ADD), has won an award in the category Excellence in Ancillary Pharma Services, at the India Pharma Awards 2019.

The India Pharma Awards bring together industry pioneers and recognize outstanding examples of innovation that improve the pharma industry. TCS was recognized for its leadership in leveraging automation, artificial intelligence (AI) and IoT through its intellectual property and commercial-off-the-shelf offerings, to digitize and transform patient engagement, metadata management and regulatory submissions for life sciences organizations.

"We are building future-proof technology platforms to transform drug development by harnessing our deep knowledge of the life sciences industry, coupled with expertise in digital and AI technologies," said **Debashis Ghosh, Global Head, Life Sciences and Healthcare, TCS**. *"This award is a testament to the advanced capabilities of our TCS ADD suite that digitally transforms clinical trials and delivers increased speed to market, improved regulatory compliance and enhanced patient experiences."*

TCS ADD is a suite of cloud-based platforms adopted by 18 leading global life sciences companies to transform their product innovation initiatives. It streamlines the entire clinical R&D value chain, spanning clinical data management, metadata management, pharmacovigilance, patient engagement, clinical operations, and data analytics and insights. The suite fosters optimized study planning, accelerates study setup and execution, manages comprehensive and new data sources, derives meaningful insights, enables adherence to safety and regulatory needs, improves patient engagement, and supports adaptive trials.

The suite is powered by a cognitive engine called 'Decision Fabric' that enables the automation of complex business processes. It leverages cloud architecture and intuitive user experience design and aligns to the Good Clinical Practice guidelines and privacy regulations.

About Tata Consultancy Services Ltd. (TCS)

Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world's largest businesses in their transformation journeys for the last 50 years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent Agile delivery model, recognized as a benchmark of excellence in software development.

A part of the Tata group, India's largest multinational business group, TCS has over 450,000 of the world's best-trained consultants in 46 countries. The company generated consolidated revenues of US $20.9 billion

in the fiscal year ended March 31, 2019, and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the Dow Jones Sustainability Index (DJSI), MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit us at www.tcs.com.

TCS media contacts:

Asia Pacific	Email: charlene.lee@tcs.com Phone: +65 9138 4370
Australia and New Zealand	Email: kelly.ryan@tcs.com Phone: +61 422 989 682
Benelux	Email: joost.galema@tcs.com Phone: +31 615 903387
Canada	Email: tia.thomas@tcs.com Email: +1 647 790 7602
Central Europe	Email: anke.maibach@tcs.com Phone: + 49 172 6615789
Europe	Email: mattias.afgeijerstam@tcs.com Phone: +46723989188
India	Email: arushie.sinha@tcs.com Phone: +91 22 6778 9960
Japan	Email: douglas.foote@tcs.com Phone: +81 80-2115-0989
Latin America	Email: martin.karich@tcs.com Phone: +569 6170 9013
Nordics	Email: roland.bagen@tcs.com Phone: +46 70 317 80 24
UK	Email: peter.devery@tcs.com Phone: +44 20 3155 2421
USA	Email: b.trounson@tcs.com Phone: +1 646 313 4594

###